News
NORD Summit Reveals 2025 Rare Disease Priorities
Avalere attendees of the National Organization of Rare Disorders (NORD) Breakthrough Summit shared a recap of themes from the conference in MedAd News.
Avalere Covered in Nephrology News
With nearly 4,000 posters presented at ASN’s annual conference, Avalere’s study of post-COVID home dialysis stands apart with a feature in Nephrology News.
Avalere Published in PM360: Research that Reflects Reality
For researchers developing new medicines and therapies, real-world data gives them an understanding of patients’ actual experiences outside of clinical trials.
Avalere Industry Outlook Report Wins 2024 Design Award
Graphic Design USA, a publication for graphic design professionals, recognized Avalere's annual report in its Inhouse Design Awards Competition.
Health Policy Veteran Emily Donaldson Joins Avalere
Emily Donaldson brings 15 years of experience supporting pharmaceutical manufacturers and health plans, focused on insurance markets and state healthcare policy.
Rethinking Evidence Strategy in HEOR Budget Planning
Avalere experts in health economics and outcomes research (HEOR) identify four elements of evidence strategy development in Pharma Focus America.
Clinical Trial Designs for Rare and Ultra-Rare Disease
In Med Ad News, Mariia Saldova shares innovative ways to overcome the challenges of planning and executing clinical trials in small patient populations
The FDA’s Final Rule on Laboratory-Developed Tests (LDTs)
Laura Housman’s article in the July issue of MedTech Intelligence explores the potential impact of the FDA’s rule to overhaul its regulation of LDTs.
An Access Path for Digital Therapeutics
Based on Brigit Kyei-Baffour’s panel presentation at BIO 2024, Med Ad News published a summary of the insights from participants.
Avalere Welcomes Industry Veteran Ashley Flint to Policy Team
Ashley Flint brings 12 years of policy experience in the life sciences industry, with deep knowledge of prescription drug pricing, access, and reimbursement.
Establishing Value in an Uncertain and Dynamic Landscape
On June 5, The Evidence Base published an article entitled, “Navigating uncertainty: redefining healthcare value in an evolving healthcare landscape,” covering key topics from Avalere’s ISPOR theater session.
Sarah Alwardt Brings Data and Technology to the Forefront in Dual Role as President of Avalere and U.S. Policy, Access, Value and Evidence at Avalere Health
Avalere is pleased to announce Sarah Alwardt, PhD as its new President.
New Roles for Avalere Senior Leadership
Avalere is pleased to announce the promotion of three leaders in its Evidence & Strategy and Market Access practices.
Avalere Announces Departure of President Elizabeth Carpenter, Appointment of Interim President Sarah Alwardt
Elizabeth Carpenter will step down as Avalere President. Sarah Alwardt will lead Avalere on an interim basis.
Avalere Health Welcomes Emily Lobelo as Vaccine Policy Lead
Emily Lobelo, who has served for 15 years at the CDC, brings extensive knowledge of the vaccine landscape to Avalere’s policy team.
Avalere Health Welcomes Lisa Joldersma as Strategic Advisor
As a strategic advisor to the Policy Practice, Lisa Joldersma adds deep expertise in Medicare, commercial and employer-based insurance, and state policy issues.
Laura Housman Joins Avalere, Strengthens Evidence & Strategy Team
As a new managing director in the Evidence & Strategy practice, Laura Housman brings deep expertise in the pharmaceutical, device, and healthcare industries.
Avalere Welcomes Return of Shareef Ghanem to Financial Services Team
Shareef Ghanem rejoins Avalere as a managing director, bringing more than 10 years of experience in due diligence, operations, and corporate strategy.
Avalere Health Announces Addition of Kelsey Lang to Policy Practice
The veteran health policy professional brings expertise in coverage, access, and reimbursement and experience working with providers, plans, and manufacturers.
Value-Based Pricing and Payment Expert Joins Avalere
Veteran health policy professional brings deep expertise in value assessment, pharmaceutical value-based pricing, and payment reform.